Business
Kelun-Biotech to Present Results of Six Clinical Studies at 2025 ASCO Annual Meeting
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK) announced that it will present results from six Kelun-led clinical studies at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago from May 30 to June 3. Results include data from its TROP2 antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT), anti-PD-L1 mAb tagitanlimab, and RET inhibitor KL590586 (A400/EP0031). The abstracts for these studies will be published on the ASCO's official website
About this update from Sichuan Kelun-biotech Biopharmaceutical Co., Ltd. Class H
[{"type":"text","content":"CHENGDU, China, April 24, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK) announced that it will present results from six Kelun-led clinical studies at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago from May 30 to June 3. Results include data from its TROP2 antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT), anti-PD-L1 mAb tagitanlimab, and RET inhibitor KL590586 (A400/EP0031). The abstracts for these studies will be published on the ASCO's official website on May 22, 2025, local time.","length":594,"tagName":"p"},{"type":"text","content":"Detailed information on the studies selected for ASCO 2025 are as follows:","length":74,"tagName":"p"},{"type":"text","content":"Title: Sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated advanced EGFR-mutated non-small cell lung cancer (NSCLC): Results from the randomized OptiTROP-Lung03 study.Presentation Type: OralAbstract Number: 8507Session Date and Time: 6/1/2025 8:00 AM-11:00 AM CDT","length":295,"tagName":"p"},{"type":"text","content":"Title: Tagitanlimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (R/M NPC): Results from a randomized, double-blind, phase 3 study.Presentation Type: OralAbstract Number: 6004Session Date and Time: 5/31/2025 1:15 PM-4:15 PM CDT","length":328,"tagName":"p"},{"type":"text","content":"Title: Sacituzumab tirumotecan (sac-TMT) as first-line treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/m TNBC): Initial results from the Phase II OptiTROP-Breast05 study.Presentation Type: Rapid oralAbstract Number: 1019Session Date and Time: 5/30/2025 2:45 PM-4:15 PM CDT","length":320,"tagName":"p"},{"type":"text","content":"Title: Sacituzumab tirumotecan (sac-TMT) in combination with tagitanlimab (anti-PD-L1) in first-line (1L) advanced non-small-cell lung cancer (NSCLC): Non-squamous cohort from the phase II OptiTROP-Lung01 study.Presentation Type: PosterAbstract Number: 8529Session Date and Time: 5/31/2025 1:30 PM-4:30 PM CDT","length":317,"tagName":"p"},{"type":"text","content":"Title: Sacituzumab Tirumotecan (sac-TMT) in patients (pts) with previously treated locally advanced or metastatic (LA/M...
More updates from Sichuan Kelun-biotech Biopharmaceutical Co., Ltd. Class H